Impact on HbA1c and body weight of switching from other GLP‐1 receptor agonists to semaglutide: A model‐based approach

AIMS: Semaglutide is a glucagon‐like peptide‐1 (GLP‐1) analogue approved for the treatment of type 2 diabetes. The impact of switching treatment from another GLP‐1 receptor agonist (GLP‐1RA) to semaglutide was investigated by analyses of exposure‐response models. METHODS: HbA1c and body weight time‐...

Descripción completa

Detalles Bibliográficos
Autores principales: Overgaard, Rune V., Lindberg, Søren Ø., Thielke, Desirée
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585654/
https://www.ncbi.nlm.nih.gov/pubmed/30047216
http://dx.doi.org/10.1111/dom.13479

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585654/
https://www.ncbi.nlm.nih.gov/pubmed/30047216
http://dx.doi.org/10.1111/dom.13479

Ejemplares similares